Eli Lilly, Boehringer's Heart Drug Jardiance Gets Priority Review from FDA

   By Kimberly Chin 
 

Eli Lilly & Co. and Boehringer Ingelheim Pharmaceuticals Inc. said Thursday that its heart drug Jardiance will be given priority review by the U.S. Food and Drug Administration as a potential treatment that could reduce the risk of cardiovascular death and hospitalization for adults with heart failure regardless of ejection fraction.

The FDA also accepted Eli Lilly and partner Boehringer's supplemental new drug application for Jardiance.

Results from an advanced trial show that Jardiance was able to reduce the relative risk of cardiovascular death or hospitalization for heart failure in adults independent of left ventricular ejection fraction--the amount of blood being pumped out of the heart's left ventricle with each contraction.

In September, the FDA gave Jardiance a breakthrough therapy designation for the treatment of adults with heart failure with preserved ejection fraction. Jardiance has also received a fast-track designation from the FDA.

Write to Kimberly Chin at [e-mail]

(END) Dow Jones Newswires

November 11, 2021 14:22 ET (19:22 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.